Autolus Therapeutics Ltd (AUTL)

NASDAQ
3.315
+0.015(+0.45%)
  • Volume:
    12,526
  • Day's Range:
    3.180 - 3.450
  • 52 wk Range:
    1.960 - 7.900

AUTL Overview

Prev. Close
3.3
Day's Range
3.18-3.45
Revenue
582K
Open
3.45
52 wk Range
1.96-7.9
EPS
-1.84
Volume
12,526
Market Cap
301.37M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
163,029
P/E Ratio
-1.81
Beta
1.39
1-Year Change
-46.95%
Shares Outstanding
90,909,783
Next Earnings Date
Nov 10, 2022
What is your sentiment on Autolus Therapeutics?
or
Vote to see community's results!

Autolus Therapeutics Ltd News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Autolus Therapeutics Ltd Analysis

Autolus Therapeutics Ltd Company Profile

Autolus Therapeutics Ltd Company Profile

Employees
326

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company’s clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellStrong SellNeutralBuySell
Technical IndicatorsStrong SellStrong SellStrong SellStrong BuyStrong Sell
SummaryStrong SellStrong SellSellStrong BuyStrong Sell
  • https://invezz.com/es/noticias/2021/11/08/blackstone-provoca-un-aumento-del-30-en-las-acciones-de-autolus-therapeutics/
    0
    • Pump. Do not dump!
      0
      • Do you have any ideas about this stock?
        0
        • In my opinion, an undervalued company. Total short term assets exceeds its short term liabilities and its long term liabilities, it is a debt free company, it has sufficient cash runway for more than a year based on its current free cash flow and it's revenue (67.8% per year) is forecast to grow faster than the US market... having said so, do your own numbers
          0